We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 05, 2021

Dimethyl Fumarate Treatment Is Ineffective for Primary Progressive MS

Neurology(R) Neuroimmunology & Neuroinflammation


Additional Info

Disclosure statements are available on the authors' profiles:

Neurology(R) Neuroimmunology & Neuroinflammation
Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis: A Randomized, Controlled Trial
Neurol Neuroimmunol Neuroinflamm 2021 Sep 01;8(5)e1037, H Højsgaard Chow, J Talbot, H Lundell, C Gøbel Madsen, L Marstrand, T Lange, MR Mahler, S Buhelt, R Holm Hansen, M Blinkenberg, J Romme Christensen, P Soelberg Sørensen, M Rode von Essen, HR Siebner, F Sellebjerg

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading